Human Albumin Csl Behring (Human Plasma Protein)

Human Albumin Csl Behring is indicated for conditions where plasma volume or albumin levels need rapid restoration.

• Treatment of hypovolemia due to acute blood loss, trauma, or dehydration.
• Management of hypoalbuminemia associated with chronic liver disease or nephrotic syndrome.
• Volume expansion in patients undergoing major surgery, such as cardiac or transplant procedures.
• Supportive therapy for extensive burns to maintain intravascular oncotic pressure.
• Adjunct in plasma exchange or therapeutic apheresis when albumin replacement is required.
• Correction of dilutional hypoalbuminemia during massive fluid resuscitation in critical care settings.

• Human Albumin Csl Behring works by increasing the concentration of albumin in the intravascular compartment, which raises plasma oncotic pressure. The elevated oncotic gradient draws water from the interstitial space into the bloodstream, expanding circulating volume. Albumin also serves as a carrier protein for endogenous substances such as hormones, fatty acids, and drugs, contributing to hemodynamic stability and supporting transport functions.

Adverse reactions to Human Albumin Csl Behring are generally infrequent but can range from mild to severe.

Common

• Fever or chills during infusion.
• Mild rash or urticaria at infusion site.
• Headache or dizziness.
• Nausea or vomiting.
• Transient hypotension during administration.
• Mild itching or pruritus.
• Elevated heart rate (tachycardia).
• Mild swelling or edema at the infusion site.
• Transient increase in serum calcium levels.

Serious

• Anaphylactic or severe allergic reaction.
• Acute respiratory distress or bronchospasm.
• Hemolysis or renal impairment.
• Thromboembolic events such as deep vein thrombosis.
• Severe hypertension or hypertensive crisis.
• Disseminated intravascular coagulation (DIC).
• Cardiac arrest or severe arrhythmias.
• Pulmonary edema due to rapid volume expansion.

When using Human Albumin Csl Behring, clinicians should observe several precautions to minimize risk and ensure appropriate patient selection.

• Verify baseline serum albumin and volume status before administration.
• Do not administer to patients with a documented allergy to human albumin or other plasma proteins.
• Monitor vital signs and fluid balance closely during and after infusion to detect overload.
• Use caution in individuals with congestive heart failure, coronary artery disease, or pulmonary hypertension.
• Adjust dose or infusion rate in patients with renal impairment or reduced hepatic function.
• Infuse slowly (not exceeding recommended rate) to reduce risk of hypotension and anaphylaxis.

Human Albumin Csl Behring may interact with certain medications or clinical conditions; awareness of these interactions helps prevent adverse outcomes.

Avoid

• Concomitant use with other volume expanders that may cause fluid overload.
• Administration with drugs that have a high protein binding displacement risk (e.g., warfarin) may alter plasma concentrations.
• Use with hyperoncotic agents such as dextran in the same infusion line.

Use with caution

• Concurrent diuretics may increase risk of electrolyte imbalance.
• Co-administration with vasopressors may require dose adjustments.
• Patients receiving renal replacement therapy may need monitoring of albumin levels.
• Use in combination with blood products may affect coagulation parameters.